---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-036841"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2025-04-21T23:59:59+00:00"
generated_at: "2026-05-23T10:32:01.301696+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MindMed amends credit facility, gets $42M new term loan; total capacity up to $120M

## Summary
- Restated credit facility provides up to $120M in term loans; $42M funded immediately to refinance existing debt.
- Interest rate lowered to greater of 10.25% or Prime+2.75%; maturity extended to April 1, 2029.
- Lenders may convert up to $7M of debt into common shares at $4.01-$9.00 per share.
- Additional $28M tranche available upon clinical/regulatory milestones; $50M discretionary tranche.
- Minimum liquidity covenant effective July 1, 2026 if milestones missed; waived if market cap >$500M.

## SEC filing metadata
- accession: 0001104659-25-036841
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2025-04-21T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000110465925036841/0001104659-25-036841-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000110465925036841/tm2512703d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-036841
- JSON: https://secwatch.observer/filing/0001104659-25-036841.json
- Plain text: https://secwatch.observer/filing/0001104659-25-036841.txt

## Key facts
- Debt Financings
  Definium Therapeutics, Inc. amended credit facility of up to $120.0 million with K2 HealthVentures LLC at the greater of (x) 10.25% and (y) the sum of (a) the Prime Rate as reported in T maturing April 1, 2029.
  - Instrument: credit facility
  - Principal: up to $120.0 million
  - Counterparty: K2 HealthVentures LLC
  - Rate: the greater of (x) 10.25% and (y) the sum of (a) the Prime Rate as reported in T
  - Maturity: April 1, 2029
  - Event: amendment
  source text: Agreement”). The First Amendment and the Amended Credit Agreement provide for, among other things: (i) an aggregate principal amount of term loans (the “Term Loans”) of up to $120.0 million, consisting of (A) a new Restatement First Tranche Term Loan (as defined in the Amended Credit Agreement) of $42.0 million, which was funded on the Effective Date, a portion of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1813814/000110465925036841/0001104659-25-036841-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.